The United Kingdom and the United States have secured a significant commercial pact that will guarantee no import taxes on British drug exports being sold in the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has pledged to boost spending on pharmaceuticals through the public health system. This move guarantees that tariffs on these vital exports will stay at nothing for a period of three years.
This deal follows recent statements to significantly raise import taxes on patented pharmaceutical products, with figures discussed up to 100%.
"This agreement between the United Kingdom bolsters the global environment for cutting-edge drugs and brings much-needed equity to transatlantic pharmaceutical trade," a statement noted.
Trade Importance
Drugs are one of the UK's largest export categories to the United States, which is clearly the biggest buyer for major companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months prior to the third quarter, the UK sold medicines valued at billions to the US. This value represented nearly one-fifth of British export trade in that timeframe.
"This agreement protects employment, boosts investment and paves the way for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary commented.
Detailed UK Commitments
The pact involves several key commitments from the British government:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to raise overall NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage manufacturers must refund to the NHS to control costs will be restricted at 15%. Previously, rebates were more than twenty percent.
Broader Context
The deal follows a ongoing dispute between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
These tensions were exacerbated by assertions that American customers were paying several times more for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several significant drug company projects in the UK have been halted or cancelled, while substantial investments have been announced toward projects in the United States.
The Science Minister publicly accepted that the NHS needed to spend more on treatments, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
